Subbu Nambi

Stock Analyst at Guggenheim

(0.71)
# 2512
Out of 5,438 analysts
44
Total ratings
Success rate
Average return
22 Stocks
Name Action PT Current % Upside Ratings Updated
CAI Caris Life Sciences
Maintains: Strong Buy
32 36
30.21 19.17% 2 Aug 13, 2025
DHR Danaher
Reiterates: Buy
250 250
199.79 25.13% 2 Jul 23, 2025
WGS GeneDx Holdings
Maintains: Strong Buy
88 115
110.65 3.93% 1 Jun 30, 2025
TEM Tempus AI
Maintains: Strong Buy
65 75
60.81 23.33% 3 Jun 30, 2025
NEOG Neogen
Maintains: Buy
13 10
5.12 95.31% 3 Jun 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
122 114
94.79 20.27% 3 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
50 50
27.63 80.96% 2 May 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
10 10
8.1 23.46% 1 Apr 16, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
60 60
40.92 46.63% 2 Apr 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Apr 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
45 37
28.01 32.1% 3 Apr 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
n/a
n/a n/a 3 Feb 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
56 56
54.81 2.17% 5 Feb 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
170 200
157.12 27.29% 2 Jan 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
n/a
n/a n/a 1 Oct 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
3.02 98.68% 1 Jun 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
0.72 733.33% 1 Jun 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 3 Jun 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
n/a
n/a n/a 1 Jun 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
25
19.13 30.68% 1 Dec 14, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
n/a
n/a n/a 1 Dec 14, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
n/a
n/a n/a 1 Dec 14, 2023